Compare BALY & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BALY | AKBA |
|---|---|---|
| Founded | 2004 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 651.4M | 729.1M |
| IPO Year | N/A | 2014 |
| Metric | BALY | AKBA |
|---|---|---|
| Price | $16.37 | $1.60 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $15.40 | $6.25 |
| AVG Volume (30 Days) | 131.7K | ★ 4.0M |
| Earning Date | 11-10-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,490,807,000.00 | $225,071,000.00 |
| Revenue This Year | $5.78 | $52.38 |
| Revenue Next Year | $4.82 | $22.45 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 0.36 | ★ 32.49 |
| 52 Week Low | $8.46 | $1.45 |
| 52 Week High | $22.41 | $4.08 |
| Indicator | BALY | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 49.31 | 40.49 |
| Support Level | $14.72 | $1.45 |
| Resistance Level | $17.80 | $1.61 |
| Average True Range (ATR) | 1.29 | 0.08 |
| MACD | -0.18 | 0.05 |
| Stochastic Oscillator | 36.26 | 62.75 |
Ballys Corp is a gaming, hospitality, and entertainment company with a portfolio of casinos and resorts and a growing omnichannel presence. It provides customers with physical and interactive entertainment and gaming experiences, including traditional casino offerings, iGaming, online bingo, sportsbook, and free-to-play (F2P) games. The company owns and operates, several casinos across the United States, one golf course in New York, one horse racetrack in Colorado, and Aspers Casino in the United Kingdom. Its Interactive International division, an interactive gaming operator concentrated in Europe, operates a lottery management and services business. The company's reportable segments are Casinos and Resorts, which derive key revenue, International Interactive and North America Interactive.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.